Aardvark Therapeutics - ARD-301 - Ownership and Business Overview

Life ScienceCompany

Aardvark Therapeutics - ARD-301 Ownership

Who owns Aardvark Therapeutics - ARD-301?

Aardvark Therapeutics - ARD-301 is owned by SCILEX Pharmaceuticals and Sorrento Therapeutics. It was acquired on March 1, 2021.

Aardvark Therapeutics - ARD-301 Business Overview

Where is Aardvark Therapeutics - ARD-301 headquartered?

Aardvark Therapeutics - ARD-301 is headquartered in San Diego, California.

What sector is Aardvark Therapeutics - ARD-301 in?

Aardvark Therapeutics - ARD-301 is a life science company.

Life Science M&A Summary in 2021

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2021. The largest life science acquisition in 2021 was Pharmaceutical Product Development - which was acquired by Thermo Fisher Scientific for $17.4B.

Subscribe to Mergr to view all 400 acquisitions of life science companies in 2021, including 47 acquisitions by private equity firms, and 353 by strategics.

Aardvark Therapeutics - ARD-301

San Diego, California 92130
United States,

Aardvark Therapeutics' ARD-301 proprietary formulation Delayed Burst Release Low Dose Naltrexone (DBR-LDN) used for the treatment of chronic pain, fibromyalgia, and chronic post-COVID syndrome. Aardvark Therapeutics' ARD-301 is based in San Diego, California.


 Subscribe to unlock this and 215,016
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.

We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore a company's M&A activity, ownership history, and connections - organized to help you uncover opportunities and make informed decisions.

With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.7K Private Equity Firms
  • 208K M&A Transactions
  • 210K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.7K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

What next?

Get Full Access

Full access to Mergr's investor, acquirer, and transaction data starts here.

Related Lists for Aardvark Therapeutics - ARD-301

Life Science Companies